Funding for this research was provided by:
Nattional Cancer Center Research and Development Fund (29-A-3)
Japan Agency for Medical Research and Development (JP19ck0106508h001)
Received: 22 August 2019
Accepted: 4 October 2019
First Online: 25 October 2019
Ethics approval and consent to participate
: This study is being conducted in accordance with the principles expressed in the Declaration of Helsinki and Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The protocol of this study was approved by the Institutional Review Board of National Cancer Center Hospital on August 23, 2017. Written informed consent has been obtained from all enrolled participants.At the time of submission (July 2019), a total of 21 institutions are participating in this trial. The participating institutions are as follows: Hokkaido University Hospital, Asahikawa Medical University Hospital, Sapporo Medical University Hospital, University of Tsukuba Hospital, Saitama Medical University International Medical Center, Saitama Medical University Hospital, National Cancer Center Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Keio University Hospital, Tokyo University Hospital, Niigata Cancer Center Hospital, Toyama Prefectural Central Hospital, Shinshu University Hospital, Shizuoka Cancer Center, Nagoya University Hospital, Kyoto University Hospital, Osaka International Cancer Institute, Fukuoka University Hospital, Kyushu University Hospital, Kumamoto University Hospital, National Hospital Organization Kagoshima Medical Center.
: Not applicable.
: The authors declare that they have no competing interests.